Curriculum Vitae Prof. Dr. Reinhard Seger

Date of birth: March 11th, 1947
Nationality: Swiss
University Children's Hospital
Immunology/HSCT
Steinwiesstrasse 75
CH-8032 Zurich
Phone: +41-76-387 7667
E-Mail: reinhard.a.seger@gmail.com

Education

1965 - 1971	MD in Human Medicine, Berlin, Germany
1972 - 1973	MSc in Exp. Immunology, Birmingham, UK
1983	Venia legendi at Faculty of Medicine, Univ. Zurich, in "Paediatric Immunology"
	Czerny Prize (Dtsche.Ges.für Kinderheilkunde), Götz Prize (Med. Faculty, Univ. Zürich)

Post-doctoral training/Academic career

1974 - 1978	Resident Paediatrics, Universities Würzburg (2 years) and Zurich (3 years)
1979 - 1983	Senior Registrar Infectiology, University Children's Hospital Zurich
1983 - 1984	Visiting Assistant Professor, Div. d'Immunologie, Hôpital Necker-Enfants Malades, Paris (Prof. C. Griscelli) + Div. of Immunol., Dept. Paediatrics, Duke University, USA (Prof.R.Buckley)
1985 - 1989	Senior Registrar Immunology, University Children's Hospital Zurich
since 1989	Head of the Div. Paediatric Immunology/BMT and Extraordinarius, Univ.Zürich
1990-	Establishment of a Paediatric Unit for BMT and a Stem Cell Laboratory
2002/3	Sabbatical (7 mo), Unité d `Immunologie, Necker-Enfants Malades Paris (Prof. A. Fischer)
since 2008	Full Professor (Ordinarius ad personam) for "Paediatric "Immunology/Haematology"
31.12.2012.	Retirement from Clinical Duties (Emeritus)

Emeritus career

2007 – 2016	Immunology/Infectiology PG courses in Kantha Bopha Children`s Hospitals, Cambodia
2015 -2023	Teaching Faculty in PID courses of Asia Pacific Society for Immune Diseases (APSID), Hongkong, Hanoi, Bangkok, Chandigarh

Active Grant Support

1980 - 1996	8 grants from Swiss National Science Foundation (Principal Investigator)
2011 - 2016	CELL-PID (Advanced Cell Therapies for treatment of Immunodeficiency) FP7 grant of EU

List of publications (5 most important)

1. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C*, **Seger R***, Grez M* (2006) *share senior authorship. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. **Nature Medicine** 12: 401-409.

2. Bianchi M, Hakkim A, Brinkmann V, Siler U, **Seger RA**, Zychlinsky A, Reichenbach J (2009). Restoration of NET formation by gene therapy in CGD controls Aspergillosis. **Blood** 114: 2619-2626

3. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D*, **Seger R***, von Kalle C*, Grez M* (2010) * equal contribution. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. **Nature Medicine** 16: 198-204.

4. Güngör T, Teira P, Slatter M, **Seger R,** Haddad E, Albert MH, Hassan M (2014). Reduced-intensity conditioning and HLA-matched HSCT in patients with CGD: A prospective multicentre study. **Lancet** 383, 436-448

5. Leung D, Chua GT, Mondragon AV, **Seger R**, Ochs HD, Singh S, Lee PP, Lau YL (2020). Current Perspectives and Unmet Needs of PID Care in Asia Pacific. **Front. Immunol**. 11: 1605